Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Non-Hodgkin Lymphoma
Clinical trial register · United States · industry-sponsored

Non-Hodgkin Lymphoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 15 Texas 14 Georgia 13 Florida 12 New York 10
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Non-Hodgkin Lymphoma trials in the USA

29 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
NCT07679919Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
Luminary Therapeutics
Phase 1
27
Ohio
2026-09
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
NCT07750886Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Natera, Inc.
Observational
200
Texas
2026-07-27
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Active, closed
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
VIVUS LLC
Phase 2
49
Arizona, California, Georgia, Illinois
2025-03-12
Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT06343311B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
Estrella Immunopharma, Inc.
Phase 1/2
27
California, Ohio, Oregon, Texas, Utah
2024-06-01
Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma
Miltenyi Biomedicine GmbH
Observational
150
Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina
2024-05-15
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Recruiting
Bristol-Myers Squibb
Observational
50
Oregon, Texas, Utah, Wisconsin
2023-10-06
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2
270
California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky, Louisiana
2023-05-09
Active, closed
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Sana Biotechnology
Phase 1
16
California, Georgia, Kansas, Michigan, Nebraska, Texas
2023-05-02
Active, closed
A Rollover Study of CC-122
NCT05688475Non-Hodgkin Lymphoma
Bristol-Myers Squibb
Phase 1
12
New York, Tennessee, Wisconsin
2023-04-11
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
Schrödinger, Inc.
Phase 1
98
Arizona, Delaware, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2023-04-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
CRISPR Therapeutics AG
Phase 1/2
120
Kansas, Missouri, Texas, Utah
2023-03-10
Recruiting
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma
Marker Therapeutics, Inc.
Phase 1
79
California, Colorado, Kansas, New York, Texas, Wisconsin
2023-01-02
Active, closed
Hoffmann-La Roche
Phase 1
121
California, Colorado, Florida, Illinois, North Carolina, Texas
2022-10-26
Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
Newave Pharmaceutical Inc
Phase 1
100
Illinois, Massachusetts, North Carolina, Ohio, Texas, Utah
2022-05-08
By invitation
Long-Term Follow-up Study
NCT05332054Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Caribou Biosciences, Inc.
Observational
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2022-03-16
Active, closed
Genentech, Inc.
Phase 2
320
Alabama, Alaska, Arizona, California, Colorado, Delaware, Florida, Iowa
2022-02-01
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
689
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2021-09-13
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Kartos Therapeutics, Inc.
Phase 1/2
84
Indiana, Ohio, Texas
2021-02-23
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
CellCentric Ltd.
Phase 1/2
250
Georgia, Indiana, Maryland, Nebraska, Pennsylvania
2019-08-09
Recruiting
Imugene Limited
Phase 1
135
Florida, Georgia, Maryland, Massachusetts, Minnesota, New York, Rhode Island, Texas
2019-03-11
Active, closed
DS-3201b in Participants With Lymphomas
NCT02732275Lymphoma, Malignant, Non-hodgkin Lymphoma
Daiichi Sankyo Co., Ltd.
Phase 1
100
California, Connecticut, Georgia, Massachusetts, New Jersey, New York, North Carolina, Ohio
2016-03-31
Active, closed
Acerta Pharma BV
Phase 1/2
113
Arizona, California, Florida, Illinois, Kentucky, Louisiana, Michigan, New Jersey
2014-12-29
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/non-hodgkin-lymphoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies listing the condition Non-Hodgkin Lymphoma.

How many Non-Hodgkin Lymphoma trials are recruiting in the US?

17 of the 29 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Hodgkin Lymphoma), 29 studies
PhaseStudiesRecruitingShare
Phase 110434.5%
Phase 1/29731%
Observational4313.8%
Phase 23110.3%
Phase 4226.9%
Phase 3103.4%

Most active sponsors

Lead sponsors with the most studies (Non-Hodgkin Lymphoma)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb21
Eli Lilly and Company22
Genmab20
Hoffmann-La Roche20
Acerta Pharma BV10
AstraZeneca11
BeOne Medicines11
Caribou Biosciences, Inc.10
CellCentric Ltd.11
CRISPR Therapeutics AG11

Top states

Top states (Non-Hodgkin Lymphoma), by number of studies with a site there
StateStudies
California15
Texas14
Georgia13
Florida12
New York10
Arizona9
Illinois9
Massachusetts8
North Carolina8
Ohio7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.